HOLOGIC INC Forms 3, 4 and 5: Restricted Stock Units and Performance Rights
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 18 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-04-07: Reporting owner Verstreken Jan; Form 4; Security Performance Stock Units; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-04-07: Reporting owner Verstreken Jan; Form 4; Security Performance Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2026-04-07: Reporting owner Schnittker Brandon; Form 4; Security Performance Stock Units; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-04-07: Reporting owner Schnittker Brandon; Form 4; Security Performance Stock Units; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-04-07 | Verstreken Jan Officer (Group President, International) | 4 | Performance Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +31,409 31,409 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | Verstreken Jan Officer (Group President, International) | 4 | Performance Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −31,409 0 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | Schnittker Brandon Officer (President, GYN Surgical) | 4 | Performance Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,432 8,432 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | Schnittker Brandon Officer (President, GYN Surgical) | 4 | Performance Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −8,432 0 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | Schneiders Jennifer M Officer (President, Diag. Solutions) | 4 | Performance Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,598 22,598 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | Schneiders Jennifer M Officer (President, Diag. Solutions) | 4 | Performance Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −22,598 0 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | Oberton Karleen Marie Officer (Chief Financial Officer) | 4 | Performance Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +42,707 42,707 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | Oberton Karleen Marie Officer (Chief Financial Officer) | 4 | Performance Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −42,707 0 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | Mitchell Essex D Officer (Chief Operating Officer) | 4 | Performance Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,154 46,154 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | Mitchell Essex D Officer (Chief Operating Officer) | 4 | Performance Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −46,154 0 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | Liddy Anne M. Officer (General Counsel) | 4 | Performance Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,452 3,452 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | Liddy Anne M. Officer (General Counsel) | 4 | Performance Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −3,452 0 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | Horvath Mark W. Officer (President, Breast & Skeletal) | 4 | Performance Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,762 7,762 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | Horvath Mark W. Officer (President, Breast & Skeletal) | 4 | Performance Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −7,762 0 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | MACMILLAN STEPHEN P Director, Officer (Chairman, President and CEO) | 4 | Performance Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +190,400 190,400 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | MACMILLAN STEPHEN P Director, Officer (Chairman, President and CEO) | 4 | Performance Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −190,400 0 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | COHN BENJAMIN JORDAN Officer (Principal Accounting Officer) | 4 | Performance Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,665 5,665 owned after | no price filed | 2026-04-09 | |
| 2026-04-07 | COHN BENJAMIN JORDAN Officer (Principal Accounting Officer) | 4 | Performance Stock Units Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −5,665 0 owned after | no price filed | 2026-04-09 |